Rothschild Investment LLC Invests $782,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rothschild Investment LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,204 shares of the medical equipment provider’s stock, valued at approximately $782,000.

A number of other large investors have also bought and sold shares of ZBH. OLD Point Trust & Financial Services N A acquired a new position in Zimmer Biomet in the fourth quarter worth $26,000. Ables Iannone Moore & Associates Inc. bought a new stake in Zimmer Biomet during the 4th quarter worth about $30,000. Crewe Advisors LLC acquired a new stake in Zimmer Biomet in the 1st quarter valued at about $31,000. Family Firm Inc. bought a new position in shares of Zimmer Biomet in the second quarter worth about $33,000. Finally, J.Safra Asset Management Corp lifted its position in shares of Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 235 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

NYSE ZBH opened at $115.46 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. The stock has a market cap of $23.51 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 2.06 and a beta of 1.01. The business has a 50 day simple moving average of $109.76 and a 200 day simple moving average of $117.37. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business posted $1.82 earnings per share. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.06 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. Zimmer Biomet’s payout ratio is presently 20.78%.

Analyst Ratings Changes

Several research analysts recently weighed in on ZBH shares. Morgan Stanley dropped their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Raymond James cut their price target on Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $130.00 to $120.00 and set a “hold” rating for the company in a research report on Tuesday, August 20th. Barclays cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research report on Friday, May 31st. Finally, Truist Financial dropped their price target on shares of Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating for the company in a research note on Tuesday, July 16th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $126.41.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.